Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Olaparib and Durvalumab Showed Meaningful Activity in BRCA-Mutant Breast Cancer

Olaparib and Durvalumab Showed Meaningful Activity in BRCA-Mutant Breast Cancer

We hear about effective new drugs for treating various cancers almost every day. In recent years, promising results from clinical trials testing combinations of these new drugs have also begun to be published. Breast cancer treatment had seen 2 new drug classes introduced over the past 5 years: PARP-inhibiting drugs and immunotherapies.

DNA repair involves enzymes including PARP. We know that inhibiting PARP produces highly effective anticancer results in people with mutations in BRCA, another DNA repair mechanism. PARP inhibitor / suppressor drugs developed from this finding have so far received approval for ovarian, prostate, breast and pancreatic cancers from the US Food and Drug Administration (FDA). For breast cancer, olaparib, a PARP inhibitor, was first approved in January 2018, followed by talazoparib in October 2018, for patients with germline (hereditary) BRCA-mutated advanced disease, receiving FDA approval for this use.

Regarding immunotherapies in breast cancer, in March 2019 the immunotherapy atezolizumab received FDA approval for use in PD-L1 positive triple-negative breast cancer in combination with chemotherapy. We also know that in hormone-positive and HER2-negative early breast cancers, adding another immunotherapy, pembrolizumab, to neoadjuvant (preoperative tumor-shrinking) treatment significantly increased pathological complete response rates, but had not yet received FDA approval.

This led to the idea of combining these two drug classes, which appear effective in certain breast cancers. For this purpose, Dr. Susan M. Domchek and colleagues reported in The Lancet Oncology a phase I / II basket-style clinical trial showing activity of olaparib plus durvalumab in a group of patients with germline BRCA-mutated, HER2-negative metastatic breast cancer.

The MEDIOLA Study

In this international study, 34 patients enrolled between June 2016 and May 2017 received olaparib 300 mg twice daily for 4 weeks, followed by olaparib 300 mg twice daily plus intravenous durvalumab 1.5 gr every 4 weeks until disease progression or unacceptable side effects. Patients had received no more than two previous lines of chemotherapy for metastatic breast cancer. The primary endpoints were safety / tolerability and the disease control rate at 12 weeks.

Treatment Efficacy

  • The disease control rate at week 12 was 80.0%.
  • An objective response was observed in 63.3% of patients.

At week 12, disease control was achieved in 24 of 30 evaluable patients (80.0%). Objective responses occurred in 19 patients (63.3%), including a complete response in 1 patient, while an additional 5 patients (17%) had stable disease for 11 weeks. At week 28, the disease control rate was 50.0%.

The median duration of response was 9.2 months. At a mean follow-up of 6.7 months, median progression-free survival was 8.2 months. At a median follow-up of 19.8 months, median overall survival was 21.5 months.

Side Effects

Grade 3 adverse events (serious side effects) occurred in 11 patients (32%), most commonly anemia (12%), neutropenia (9%) and pancreatitis (6%). A total of six serious adverse events occurred in four patients (12%), consisting of anemia, hemolysis, hypercalcemia, dyspnea, pancreatitis and hydronephrosis. Olaparib dose reductions due to adverse effects occurred in six patients (18%). Adverse events led to treatment discontinuation in three patients because of anemia, arthralgia and shortness of breath. No treatment-related deaths were reported.

Conclusion

We knew that olaparib was effective in BRCA-mutant breast cancer. This study produced promising results suggesting that adding durvalumab may substantially increase treatment efficacy even in patients who have received multiple previous lines of therapy. Although serious side effects occurred in one of every 3 patients, the absence of reported deaths due to adverse effects suggests that unwanted events associated with this combination may be manageable. A larger, randomized phase-III study is needed to establish the effectiveness of combining a PARP inhibitor with immunotherapy in germline BRCA-mutant advanced breast cancer.

Sources

Susan M Domchek et al.
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
The LANCET Oncology, 6 August 2020.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Olaparib and Durvalumab Showed Meaningful Activity in BRCA-Mutant Breast Cancer

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy